NCT00903968View on ClinicalTrials.gov

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 1, 2009

Primary Completion Date

June 30, 2016

Study Completion Date

October 31, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Plerixafor

DRUG

bortezomib

DRUG

Dexamethasone

Trial Locations (5)

19124

Cancer Treatment Centers of America (Eastern Regional Medical Center), Philadelphia

02115

Dana-Farber Cancer Institute, Boston

02601

Cape Cod Hospital, Hyannis

01757

Milford Hospital, Milford

02462

Newton-Wellesley Hospital, Newton

Sponsors
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Genzyme, a Sanofi Company

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00903968 - Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter